Yingsi Zhou

机构：Chinese Academy of Sciences, Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Shanghai Institute of Materia Medica, NewGen Therapeutics (United States)

发表论文 43 篇 · 总被引 2829 次 · h-index 21

代表论文

• High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects (2022 · Nature Biotechnology · 被引 233)
• Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing (2023 · Nature Communications · 被引 98)
• Development of miniature base editors using engineered IscB nickase (2023 · Nature Methods · 被引 92)
• Programmable deaminase-free base editors for G-to-Y conversion by engineered glycosylase (2023 · National Science Review · 被引 78)
• Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase (2024 · Nature Communications · 被引 52)
• Engineering a transposon-associated TnpB-ωRNA system for efficient gene editing and phenotypic correction of a tyrosinaemia mouse model (2024 · Nature Communications · 被引 44)